Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irofulven in Recurrent Malignant Gliomas
NCT00012038Phase 2Completed
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
- Start
- Jul 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of irofulven in malignant glioma, astrocytoma, Oligodendroglioma (OG) and 1 more (2 arms), sponsored by New Approaches to Brain Tumor Therapy Consortium. Primary endpoints: Maximum Tolerated Dose up to 4 weeks and Pharmacokinetics. Started Jul 2001; status: completed.
02
Drugs
irofulven
03
Conditions
malignant gliomaastrocytomaOligodendroglioma (OG)glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00012038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00012038.